Stock Analysis
Teva Pharmaceutical Industries LimitedTEVA
P/E 68.56×· 5Y range 11.18–68.56×· top 0% of history
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy7 analystsP/E 68.6× sits at the 100th percentile of its 5.0513347022587265-year history.
Cash covers 22% of debt · Q2 2026.
PMP Verdict
Mixed fundamentals, expensive valuation
Strengths
- Growth81
Risks
- Valuation30
- Financial Health24
Mixed fundamentals at a demanding price.
Bull Case
- ✓Piotroski F-Score 7/9 — high earnings quality
What's happening with TEVA
Profile
Strong growth; financial health, valuation and profitability lag behind.
How is each axis scored?
- Valuation30/100 · Weak
- P/E vs own history (100th pct)0/25
- FCF yield (2.8%)5/25
- P/S (2.8x)20/25
- EV/EBIT (29.2x)5/25
- Growth81/100 · Strong
- Revenue CAGR (2.1%)6/25
- Net income CAGR (35.6%)25/25
- EPS CAGR 5Y (33.9%)25/25
- Fwd implied growth (378.3%)25/25
- Profitability35/100 · Weak
- ROIC (7.9%)5/25
- ROE (9.1%)12/25
- Net margin (4.1%)6/25
- Operating margin (12.2%)12/25
- Financial Health24/100 · Weak
- Altman Z (0.63)3/25
- Current ratio (0.88)6/25
- Interest coverage (2.4x)10/25
- Net cash / debt (D/A 33%)5/25
- Quality53/100 · Moderate
- Piotroski F (7/9)22/25
- Beneish M (-2.51)25/25
- FCF conversion (n/a)0/25
- Margin stability (σ 19.0%)6/25
- Moat58/100 · Moderate
- ROIC >12% years (5/9 yrs)13/25
- Median gross margin (47.8%)20/25
- FCF-positive years (9/9 yrs)25/25
- Worst-year net margin (worst -72.7%)0/25
Risk Flags
- ⚠Altman Z 0.6 — distress-zone balance sheet
- ⚠7 loss-making years in recent history
- ⚠Interest coverage 2.4× — thin debt cushion
- ⚠P/E 68.6× at top 0% of 5-year history
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Show more
Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Headquarters: TEL AVIV · Employees: 32,842 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
30DP/E (TTM)68.5xD
Grade D: ExpensivePrice / TTM EPS (own statements) — vs own 5Y history: 11.2x–68.6x · highest in history
P/FCF31.2xC
Grade C: ExpensivePrice / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield2.8%C
Grade C: LowTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -1.3%–14.0% · 21st pct
P/S (TTM)2.79xB
Grade B: FairPrice / TTM Revenue (own statements) — vs own 5Y history: 0.5x–2.8x · highest in history
EV/EBIT29.2xD
Grade D: ExpensiveEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 5Y history: 3.6x–92.1x · 70th pct
EV/Sales3.6xB
Grade B: FairEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E14.3xA
Grade A: CheapPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio6.23xC
Grade C: ExpensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
35DROIC7.9%D
Grade D: LowNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE9.1%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA1.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin4.1%D
Grade D: LowNet Income / Revenue
Operating Margin12.2%C
Grade C: AverageTTM EBIT / TTM Revenue
Gross Margin52.5%A
Grade A: PremiumGross Profit / Revenue
FCF Margin7.8%D
Grade D: LowFCF / Revenue
True FCF Margin6.8%C
Grade C: AverageTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
81ARevenue CAGR2.1%D
Grade D: LowCompound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR35.6%A
Grade A: HighCompound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)33.9%A
Grade A: HighCompound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth378.3%A
Grade A: HighAnalyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+5.3%C
Grade C: DilutiveShare count change over 5Y
SBC / Net Income23.8%D
Grade D: HighStock-based comp/Net income. >30% = dilution risk
SBC / Revenue1.0%A
Grade A: LowTTM stock-based comp / TTM Revenue
Financial Health
24EAltman Z-Score0.63D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio0.88xD
Grade D: LowCurrent Assets/Liabilities
Quick Ratio0.61xC
Grade C: Ok(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage2.4xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt Repayment9.8yC
Grade C: AverageYears to repay net debt via FCF
Net Debt/EBIT6.3xD
Grade D: HighLeverage. <2x Low, >4x High
Debt/Equity2.18xD
Grade D: HighDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.22xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Quality
53CPiotroski F-Score7/9A
Grade A: StrongFinancial strength 0–9. >7 Strong
Beneish M-Score-2.51A
Grade A: SafeEarnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability19.0%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue3.2%A
Grade A: Asset-lightTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.43xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Savage Brian Filed | Savage Brian | Option exercise | -4503 | |
Savage Brian Filed | Savage Brian | SellOpen market sale | -314 | |
Savage Brian Filed | Savage Brian | SellOpen market sale | -2525 | |
Savage Brian Filed | Savage Brian | SellOpen market sale | -4503 | |
Savage Brian Filed | Savage Brian | Option exercise | +4.5K |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
MIGNONE ROBERTO Filed | MIGNONE ROBERTO | SellOpen market sale | -367600 | |
Weiss Amir Filed | Weiss Amir | Option exercise | -2500 | |
Weiss Amir Filed | Weiss Amir | SellOpen market sale | -2500 |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
58CROIC >12% Years5/9 yrsC
Grade C: ModerateShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)47.8%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years9/9 yrsA
Grade A: DurableShare of completed fiscal years with positive free cash flow
Net Margin Floor-72.7%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)$0.61
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$3.14
Cash & short-term investments per share (Finnhub)
Book Value / Share$6.65
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$16.89B
Total debt obligations (short + long term)
Cash & Equiv.$3.65B
Cash and short-term investments
Net Debt$13.24B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$7.76B
Shareholders' equity (book value)
Asset / Liability1.24xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$48.33B
Current Market Capitalization
Beta0.45B
Grade B: DefensivePrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Teva Pharmaceutical Industries Limited (TEVA)
TEVA is up 0.95% at the last close. Teva Pharmaceutical Industries Limited meets 7 of 9 Piotroski F-Score criteria, placing its fundamental strength in the top tier of US-listed stocks. Altman Z-Score of 0.63 is below the 1.81 distress threshold — an elevated financial-risk flag. Beneish M-Score of -2.51 suggests a low likelihood of earnings manipulation.
- Takes ~9.8 years to repay net debt from free cash flow.
- Teva Pharmaceutical Industries Limited posted a net loss in 7 of 9 available completed fiscal years (2017–2025).
- At a valuation score of 30/100, TEVA trades at a premium to its historical multiples (P/E 68.5).
See how TEVA ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all TEVA moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 9 | Pre-market | 40.90 | +4.20% | 2.09 |
| Oct 9 | Regular | 41.21 | +4.99% | 2.51 |
| Oct 9 | After-hours | 41.21 | +4.99% | 2.51 |
| Sep 21 | Regular | 40.50 | +3.90% | 2.60 |
Frequently Asked Questions about TEVA
What is the current Teva Pharmaceutical Industries Limited (TEVA) stock price?
TEVA is trading at $41.50 at the last market close, up 0.95% on the session. PreMarketPrice tracks TEVA pre-market, intraday and after-hours prices.
Is TEVA stock a buy right now?
PreMarketPrice's quantitative model rates Teva Pharmaceutical Industries Limited's financial health at 24/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is TEVA stock overvalued?
Teva Pharmaceutical Industries Limited trades at a trailing P/E of 68.5 and our valuation score rates it 30/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Teva Pharmaceutical Industries Limited report earnings?
No confirmed earnings date is currently scheduled for TEVA. The Earnings section lists recent reports and updates as dates are announced.
What sector does Teva Pharmaceutical Industries Limited operate in?
Teva Pharmaceutical Industries Limited operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Teva Pharmaceutical Industries Limited do?
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer.
About Teva Pharmaceutical Industries Limited (TEVA) Stock
Teva Pharmaceutical Industries Limited (TEVA) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Teva Pharmaceutical Industries Limited is trading at $41.50, up 0.95% on the day with a market capitalization of $48.3 billion. The financial health score for TEVA is 24/100, which indicates poor financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for TEVA stock.
TEVA Stock Analysis & Key Metrics
On PreMarketPrice, you can track Teva Pharmaceutical Industries Limited (TEVA) across multiple dimensions:
- Pre-market price & movement: Real-time TEVA stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for TEVA with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Teva Pharmaceutical Industries Limited across multiple reporting periods.
- Financial health score: A composite score of 24/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for TEVA.
- Sector peers: Compare TEVA against 6 other healthcare stocks on key financial metrics.
Is TEVA a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Teva Pharmaceutical Industries Limited (TEVA) as an investment. The financial health score of 24/100 suggests poor financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Teva Pharmaceutical Industries Limited (TEVA) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.